08.30 – 08.45 h
|
Welcome.
Bart De Wever, ALTEXA Development, Monaco IVTIP Board / Executive Secretary, Monaco. |
08.45 – 09.30 h
|
Quality assessment of toxicity studies on nanomaterials.
Jeffrey W. Card, Senior Program Manager, Toxicology Intertek Cantox, Ontario, Canada. |
09.30 – 10.15 h
|
Nanomaterial measurement: the role of standardization and harmonization.
Christoph Klein, Program Manager Institute for Reference Materials and Measurements JRC, European Commission, Belgium |
| 10.15 – 10.45 h |
Coffee Break. |
10.45 – 11.30 h
|
Experimental nanotoxicity testing in vivo and in vitro.
Frieke Kuper, Senior Scientist Quality of Life, TNO, The Netherlands. |
11.30 – 12.15 h
|
Regulatory issues and nanomaterial risks.
Steffi Friedrich, Director General, The Nanotechnology Industry Association, Belgium. |
| 12.15 – 13.30 h |
Lunch. |
13.30 – 14.15 h
|
In vitro models of biological barriers for safety and efficacy testing of nanomedicines.
Claus-Michael Lehr, Head, Department of Drug Delivery Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Germany. |
14.15 – 15.00 h
|
The in vivo fate of nanomedicines and nanotoxicity.
Elias Fattal, Director UMR CNRS 8612. University of Paris Sud, School of Pharmacy, France. |
| 15.00 – 15.30 h |
Coffee Break. |
15.30 – 16.10 h
|
Advances and challenges when investigating toxicological responses to inhaled nanoparticles at the in vitro level.
Tobias Stoeger, Head Institute of Inhalation Biology Helmholtz Zentrum München, Germany. |
16.10 – 16.30 h
|
Human skin organ culture as a potential non animal model for safety evaluation of metallic nanoparticles.
Myriam Oron, R&D Manager of Clineral, Chemist of the Medical Division AHAVA Dead Sea Laboratories, Israel. |
16.30 – 16.50 h
|
New advances in the toxicological evaluation of nanomaterials.
Blanca Suárez, Head of Biomedicine Unit GAIKER-IK4 Technology Center, Spain. |
| 16.50 – 17.35 h |
Presentation of 3 selected posters. |
| 17.35 – 18.00 h |
Round Table. |